Aerosolized Fluoroquinolone Formulations with Cations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary infections, particularly those caused by gram-negative bacteria like Pseudomonas aeruginosa, face challenges due to antibiotic resistance and the need for high systemic concentrations, which can lead to toxicity and diminished efficacy, especially in conditions like cystic fibrosis, where aerosolized tobramycin's utility is limited by resistance and binding to sputum components.
Innovation Solution
Formulating aerosolized fluoroquinolones with divalent or trivalent cations such as magnesium, calcium, or zinc to enhance pulmonary availability, achieving higher concentrations in lung sputum and prolonged exposure, thereby improving bactericidal activity and reducing resistance emergence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of antibiotics are administered to achieve effective concentrations at the site of infection, then antibacterial efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The invention divides the treatment approach into local and systemic components by administering antibiotics directly to the lung via aerosol inhalation. This local delivery method segments the drug distribution, concentrating the antibiotic at the infection site while minimizing systemic circulation, thereby achieving effective local concentrations without proportionally increasing systemic toxicity
Solution Approach 2:
The invention uses aerosol particles as an intermediary delivery vehicle to transport the antibiotic from the external environment directly to the lung tissue. This intermediary system enables targeted delivery through the respiratory tract, allowing the drug to reach the infection site without requiring high systemic concentrations that would cause toxicity
2Reliability
If high doses of antibiotics are administered to maintain effective concentrations, then treatment efficacy is improved, but development of resistance increases
Solution Approach 1:
The invention applies local quality by creating a high concentration gradient specifically at the infection site within the lung. By delivering the antibiotic directly to the affected tissue through aerosol inhalation, the drug achieves locally high concentrations that are bactericidal and prevent resistance development, while avoiding the need for uniformly high systemic doses that would exert selective pressure throughout the body
3Reliability
If aerosolized antibiotics are administered to achieve high local concentrations, then pulmonary availability is improved, but binding to sputum components reduces efficacy
Solution Approach 1:
The invention changes the physicochemical parameters of the antibiotic formulation by using aerosol delivery, which alters the drug's physical state from systemic circulation to particulate suspension in the respiratory tract. This parameter change affects how the drug interacts with sputum components, potentially reducing non-specific binding compared to systemic administration while maintaining high local concentrations through the aerosol medium
Data Source
AI summary
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.